InspireMD CEO buys 46,154 shares in offering
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
InspireMD, Inc. (NSPR) CEO and President Marvin Slosman reported buying 46,154 common shares and 34,616 Series L common stock warrants in the issuer’s underwritten public offering on November 13, 2026. The combined public offering price was $0.65 per share of common stock and accompanying warrants. After the transactions, he directly held 3,602,812 common shares and 34,616 warrants. The form reports no Rule 10b5-1 plan for these transactions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Series L Common Stock Warrant F2 | 34,616 | $0.00 | $0.00 |
| Purchase | Common Stock F1 | 46,154 | $0.65 | $30K |
Footnotes (2)
- F1. Represents shares of common stock purchased by the Reporting Person in the Issuer's underwritten public offering at a combined public offering price of $0.65 per share of common stock and accompanying Series L common stock warrants.
- F2. The Series L common stock warrants are immediately exercisable at an exercise price of $0.65 per share and expire on November 16, 2027.
Key Figures
Key Terms
underwritten public offering financial
Series L common stock warrants technical
immediately exercisable technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the terms of the NSPR Series L warrants Slosman purchased?
AI-generated analysis. How Rhea-AI works. Not financial advice.